Harrow opened higher at $29.54, compared with its previous close of $29.37. In the last trading session, the stock traded between - and -. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Harrow is now worth
$ 253.63
Giving a profit of
$ 153.63 (153.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.07 (-3.63%)
Day High
-
Day Low
-
Day Open
$29.54
Prev Close
$29.37
Volume
4,52,599
1W Return
-1.67%
1M Return
-2.74%
3M Return
-28.23%
6M Return
-25.59%
1Y Return
-26.94%
Fundamentals
Market Cap ($ Mn)
1,062
PE Ratio
-
PB Ratio
92.01
PEG Ratio
-
ROE
-9.34%
ROCE
9.73%
EPS (TTM)
$0.26
Investment Returns
1 Week
-1.67%
1 Month
-2.74%
3 Months
-28.23%
6 Months
-25.59%
9 Months
-41.83%
Financials
Quarterly
All values in $ Mn
71.6
Sep 25
89.1
Dec 25
0.0
Mar 26
44.2
Mar 26
70.7
Jun 26
99.3
Sep 26
Updates
10Nov
Harrow Affirms FY26 Sales Guidance of $350M-$365M
Harrow Inc affirms FY26 sales guidance of $350 million to $365 million. Guidance range remains unchanged from previous outlook. Analyst consensus estimate stands at $349.747 million. Lower bound of guidance exceeds current market estimates.
3 days ago
7Oct
BTIG reiterates Buy on Harrow, maintains $63 price target
BTIG analyst Thomas Shrader reiterated a Buy rating on Harrow. The firm maintained its $63 price target for the stock. The action reflects continued confidence in the current investment thesis.
1mo ago
1Sep
Harrow to participate in three investor conferences in New York this September
Harrow management to attend three investor conferences in New York in September. Fireside chats scheduled for Sept 9 at Cantor and Sept 15 at H.C. Wainwright. Live webcasts available on company website with 90-day replay access. One-on-one investor meetings offered at all three events.
2mo ago
21Aug
Harrow IHEEZO cuts eye-injection discomfort by more than half
IHEEZO reduced patient-reported discomfort by 58% vs proparacaine in bilateral injections. Statistically significant differences observed at all four post-injection assessments. Largest absolute difference of 1.62 points recorded at two minutes post-procedure. William Blair maintains Outperform rating, citing long-term growth and compliance benefits.
Harrow Inc. delivered Q2FY26 revenue of $70.7 million, beating estimates with 11% YoY growth led by VEVYE and IHEEZO. Despite a net loss of $(17.27) million due to higher operating costs, the company announced the TYRVAYA acquisition and maintained its FY26 revenue and Adjusted EBITDA guidance.
3mo ago
11Aug
Harrow affirms FY26 sales guidance of $350-365M vs $348.468M est
Harrow reaffirms its FY26 sales guidance of $350 million to $365 million, which exceeds the consensus estimate of $348.468 million. The unchanged outlook reflects management's confidence in meeting or beating analyst expectations for the fiscal year.
